HLVX - HilleVax EV/EBITDA Multiple

The HilleVax, Inc. (HLVX) clinical pipeline is currently undergoing deep optimization, making the visual representation of EV/EBITDA quotes a critical monitoring tool. The current metric stands at . The business relies on the development of a unique norovirus drug with massive market potential. However, the company's stability depends on test results and its ability to withstand pressure within the infectious disease segment.

HLVX HilleVax Inc.: Business Value to Operating Income Before Depreciation in the range 07/04/2022 - 11/15/2026

Analytical breakdowns for HilleVax, Inc.

- stock price and consensus target price:

Stock Quotes HilleVax, Inc.|HLVX - Price Target Chart

- market capitalization statistics:

Market Capitalization HilleVax Corp|HLVX - Company Buyout Price

- issuer book value statistics:

Net Assets per Single Share HilleVax|HLVX - Accounting Value of Company|Market Cap to Net Assets Ratio hillevax.com|HLVX - Company Total Assets

- company liabilities and liquidity data:

- business earnings and investment ratios data:

HLVX - Company Net Income|Projected Future Earnings HilleVax, Inc.|HLVX - Market Cap to Earnings|Projected Price to Earnings HilleVax|HLVX - Price/Earnings to Growth Ratio|EV/EBITDA Multiple HilleVax|HLVX - Operating profit EBITDA|Net earnings per share for the last 12 months HilleVax|HLVX - Earnings per share for the last 12 months|Year-over-year net earnings per share growth for the last 12 months hillevax.com|HLVX - Earnings per share increase in current year|Earnings growth forecast for next year HilleVax, Inc.

- company sales and revenue statistics:

HLVX - Company Gross Revenue|Company Projected Revenue HilleVax|HLVX - Market Cap to Revenue Ratio|Forward P/S Multiple HilleVax Inc|HLVX - Revenue Growth YoY (Last 12 Months)

Summary company analysis:hillevax.com HLVX

This indicator compares the total enterprise value, including net debt, with its operating profitability before depreciation and amortization, allowing market speculation to be decoupled from actual cash flow. By analyzing the EV/EBITDA ratio in light of operating profit and amortization, an investor assesses the asset value of HilleVax, Inc. (HLVX) through the lens of patent protection and high barriers to entry in the norovirus vaccine segment.

Analysis of competing companies

Gilead Sciences, Inc. - Enterprise Value to EBITDA Ratio|Cidara Therapeutics, Inc. - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Novavax Inc - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio CureVac NV CVAC|Valneva Pharma (VALN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Vir Corp (VIR) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio SIGA|Emergent BioSolutions (EBS) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Atea Pharma (AVIR)|Total Company Value to Operating Income Before Depreciation Ratio Invivyd|EV/EBITDA Multiple ENTA (enanta.com)|INO: Enterprise Value to Operating Income Before Depreciation|Kalaris Tx - EV/EBITDA Multiple|Company Value to EBITDA dyadic.com|NanoViricides, Inc. (NNVC) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TLPH (Talphera Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cocrystal|Enterprise Value to EBITDA Ratio trawspharma.com (TRAW)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Dogwood Therapeutics, Inc. (DWTX)|Total Company Value to Operating Income Before Depreciation Ratio Qualigen Therapeutics|EV/EBITDA Multiple ALVR (allovir.com)|EV/EBITDA Multiple VBI Vaccines Inc VBIV|VIRI: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation VXRT (vaxart.com)